Corvus Pharmaceuticals (FRA:C17) Ending Cash Position : €8.35 Mil (As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Corvus Pharmaceuticals Ending Cash Position?

Corvus Pharmaceuticals's Ending Cash Position for the quarter that ended in Dec. 2024 was €8.35 Mil.

Corvus Pharmaceuticals's quarterly Ending Cash Position declined from Jun. 2024 (€13.79 Mil) to Sep. 2024 (€4.22 Mil) but then increased from Sep. 2024 (€4.22 Mil) to Dec. 2024 (€8.35 Mil).

Corvus Pharmaceuticals's annual Ending Cash Position declined from Dec. 2022 (€12.42 Mil) to Dec. 2023 (€11.57 Mil) and declined from Dec. 2023 (€11.57 Mil) to Dec. 2024 (€8.35 Mil).

Corvus Pharmaceuticals Ending Cash Position Historical Data

The historical data trend for Corvus Pharmaceuticals's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corvus Pharmaceuticals Ending Cash Position Chart

Corvus Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Ending Cash Position

Get a 7-Day Free Trial

13.53

56.16

12.42

11.57

8.35

Corvus Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Ending Cash Position	Get a 7-Day Free Trial															11.57	6.86	13.79	4.22	8.35

Corvus Pharmaceuticals Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Corvus Pharmaceuticals's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	12.052	+	-3.705
	=	8.35

Corvus Pharmaceuticals's Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	4.469	+	3.878
	=	8.35

Corvus Pharmaceuticals Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Corvus Pharmaceuticals's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Corvus Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corvus Pharmaceuticals Inc (FRA:C17) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

CRVS:USA

Address

901 Gateway Boulevard, Third Floor, South San Francisco, CA, USA, 94080

Website

https://www.corvuspharma.com

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Corvus Pharmaceuticals Headlines

No Headlines